Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01688934 · ClinicalTrials.gov registry record · Phase 2
Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee
A Phase 2 study, sponsored by Purdue Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
NCT01688934: Completed Phase 2 study, sponsored by Purdue Pharma.
NCT01688934 is a Phase 2 study that has completed, run by Purdue Pharma. The registered enrollment target is 230 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01688934, a Phase 2 study, has completed, sponsored by Purdue Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the analgesic efficacy of 2 dose levels of V116517 versus placebo.
Interventions
- DRUG Placebo
- DRUG V116517 50-mg tablets
- DRUG V116517 30-mg tablets
- DRUG Naproxen 500-mg capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
What the finished NCT01688934 record still lists
NCT01688934 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01688934 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01688934 about?
NCT01688934 is a clinical study titled "Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee". The primary objective of this study is to evaluate the analgesic efficacy of 2 dose levels of V116517 versus placebo.
What is the current status of trial NCT01688934?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2012-09. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01688934?
The interventions under investigation include: Placebo (DRUG), V116517 50-mg tablets (DRUG), V116517 30-mg tablets (DRUG), Naproxen 500-mg capsules (DRUG).
Who is sponsoring clinical trial NCT01688934?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01688934's enrollment target sits among peer trials
230 257th of 2000 higher than 1,737 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia